MACROGENICS INC (MGNX) Fundamental Analysis & Valuation

NASDAQ:MGNX • US5560991094

Current stock price

3.19 USD
+0.01 (+0.31%)
At close:
3.25 USD
+0.06 (+1.88%)
After Hours:

This MGNX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MGNX Profitability Analysis

1.1 Basic Checks

  • In the past year MGNX has reported negative net income.
  • MGNX had a negative operating cash flow in the past year.
  • MGNX had negative earnings in each of the past 5 years.
  • MGNX had a negative operating cash flow in each of the past 5 years.
MGNX Yearly Net Income VS EBIT VS OCF VS FCFMGNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M -200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -29.05%, MGNX is in the better half of the industry, outperforming 67.25% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -134.23%, MGNX is doing worse than 62.02% of the companies in the same industry.
Industry RankSector Rank
ROA -29.05%
ROE -134.23%
ROIC N/A
ROA(3y)-19.23%
ROA(5y)-32.14%
ROE(3y)-65.96%
ROE(5y)-73.32%
ROIC(3y)N/A
ROIC(5y)N/A
MGNX Yearly ROA, ROE, ROICMGNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • MGNX has a better Gross Margin (75.91%) than 83.33% of its industry peers.
  • MGNX's Gross Margin has declined in the last couple of years.
  • MGNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.27%
GM growth 5YN/A
MGNX Yearly Profit, Operating, Gross MarginsMGNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. MGNX Health Analysis

2.1 Basic Checks

  • MGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MGNX has more shares outstanding
  • Compared to 5 years ago, MGNX has more shares outstanding
  • Compared to 1 year ago, MGNX has a worse debt to assets ratio.
MGNX Yearly Shares OutstandingMGNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
MGNX Yearly Total Debt VS Total AssetsMGNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -5.71, we must say that MGNX is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of MGNX (-5.71) is worse than 66.47% of its industry peers.
  • A Debt/Equity ratio of 1.26 is on the high side and indicates that MGNX has dependencies on debt financing.
  • MGNX has a Debt to Equity ratio of 1.26. This is in the lower half of the industry: MGNX underperforms 77.13% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Altman-Z -5.71
ROIC/WACCN/A
WACC9.37%
MGNX Yearly LT Debt VS Equity VS FCFMGNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 5.10 indicates that MGNX has no problem at all paying its short term obligations.
  • MGNX has a Current ratio (5.10) which is comparable to the rest of the industry.
  • MGNX has a Quick Ratio of 4.92. This indicates that MGNX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 4.92, MGNX is in line with its industry, outperforming 55.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.1
Quick Ratio 4.92
MGNX Yearly Current Assets VS Current LiabilitesMGNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MGNX Growth Analysis

3.1 Past

  • The earnings per share for MGNX have decreased by -9.26% in the last year.
  • The Revenue has decreased by -0.31% in the past year.
  • Measured over the past years, MGNX shows a small growth in Revenue. The Revenue has been growing by 7.34% on average per year.
EPS 1Y (TTM)-9.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8%
Revenue 1Y (TTM)-0.31%
Revenue growth 3Y-0.53%
Revenue growth 5Y7.34%
Sales Q2Q%113.03%

3.2 Future

  • Based on estimates for the next years, MGNX will show a decrease in Earnings Per Share. The EPS will decrease by -0.57% on average per year.
  • MGNX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.20% yearly.
EPS Next Y-71.46%
EPS Next 2Y-17.21%
EPS Next 3Y-42.53%
EPS Next 5Y-0.57%
Revenue Next Year-39.38%
Revenue Next 2Y-20.91%
Revenue Next 3Y5.84%
Revenue Next 5Y1.2%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
MGNX Yearly Revenue VS EstimatesMGNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
MGNX Yearly EPS VS EstimatesMGNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. MGNX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MGNX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MGNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGNX Price Earnings VS Forward Price EarningsMGNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGNX Per share dataMGNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

  • A cheap valuation may be justified as MGNX's earnings are expected to decrease with -42.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.21%
EPS Next 3Y-42.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MGNX Dividend Analysis

5.1 Amount

  • No dividends for MGNX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MGNX Fundamentals: All Metrics, Ratios and Statistics

MACROGENICS INC

NASDAQ:MGNX (4/24/2026, 8:00:01 PM)

After market: 3.25 +0.06 (+1.88%)

3.19

+0.01 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-09
Earnings (Next)05-13
Inst Owners65.09%
Inst Owner Change0.03%
Ins Owners1.18%
Ins Owner Change1.16%
Market Cap202.76M
Revenue(TTM)149.50M
Net Income(TTM)-74.62M
Analysts75.38
Price Target4.08 (27.9%)
Short Float %6.16%
Short Ratio3.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)88.12%
Min EPS beat(2)22.41%
Max EPS beat(2)153.84%
EPS beat(4)4
Avg EPS beat(4)50.71%
Min EPS beat(4)8.09%
Max EPS beat(4)153.84%
EPS beat(8)6
Avg EPS beat(8)60.81%
EPS beat(12)7
Avg EPS beat(12)19.44%
EPS beat(16)9
Avg EPS beat(16)21.4%
Revenue beat(2)2
Avg Revenue beat(2)232.15%
Min Revenue beat(2)78.5%
Max Revenue beat(2)385.79%
Revenue beat(4)4
Avg Revenue beat(4)189.3%
Min Revenue beat(4)78.5%
Max Revenue beat(4)385.79%
Revenue beat(8)5
Avg Revenue beat(8)83.51%
Revenue beat(12)5
Avg Revenue beat(12)32.75%
Revenue beat(16)8
Avg Revenue beat(16)29.47%
PT rev (1m)17.65%
PT rev (3m)17.65%
EPS NQ rev (1m)-7.47%
EPS NQ rev (3m)5.27%
EPS NY rev (1m)-3.85%
EPS NY rev (3m)-8.39%
Revenue NQ rev (1m)-3.73%
Revenue NQ rev (3m)69.1%
Revenue NY rev (1m)23.08%
Revenue NY rev (3m)23.08%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.36
P/FCF N/A
P/OCF N/A
P/B 3.65
P/tB 3.65
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-2.02
Fwd EYN/A
FCF(TTM)-1.31
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS2.35
BVpS0.87
TBVpS0.87
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -29.05%
ROE -134.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.91%
FCFM N/A
ROA(3y)-19.23%
ROA(5y)-32.14%
ROE(3y)-65.96%
ROE(5y)-73.32%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.27%
GM growth 5YN/A
F-Score3
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.69%
Cap/Sales 1.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.1
Quick Ratio 4.92
Altman-Z -5.71
F-Score3
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)31.38%
Cap/Depr(5y)35.94%
Cap/Sales(3y)2.25%
Cap/Sales(5y)3.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8%
EPS Next Y-71.46%
EPS Next 2Y-17.21%
EPS Next 3Y-42.53%
EPS Next 5Y-0.57%
Revenue 1Y (TTM)-0.31%
Revenue growth 3Y-0.53%
Revenue growth 5Y7.34%
Sales Q2Q%113.03%
Revenue Next Year-39.38%
Revenue Next 2Y-20.91%
Revenue Next 3Y5.84%
Revenue Next 5Y1.2%
EBIT growth 1Y34.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-35.42%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.53%
OCF growth 3YN/A
OCF growth 5YN/A

MACROGENICS INC / MGNX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MACROGENICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to MGNX.


What is the valuation status of MACROGENICS INC (MGNX) stock?

ChartMill assigns a valuation rating of 0 / 10 to MACROGENICS INC (MGNX). This can be considered as Overvalued.


How profitable is MACROGENICS INC (MGNX) stock?

MACROGENICS INC (MGNX) has a profitability rating of 1 / 10.


What is the expected EPS growth for MACROGENICS INC (MGNX) stock?

The Earnings per Share (EPS) of MACROGENICS INC (MGNX) is expected to decline by -71.46% in the next year.